{"id":"https://openalex.org/W4404495039","doi":"https://doi.org/10.47392/irjaem.2024.0481","title":"Synthesis and Characterization of Chiral Impurities of Mirabegron, Used as an Overactive Bladder Drug","display_name":"Synthesis and Characterization of Chiral Impurities of Mirabegron, Used as an Overactive Bladder Drug","publication_year":2024,"publication_date":"2024-11-16","ids":{"openalex":"https://openalex.org/W4404495039","doi":"https://doi.org/10.47392/irjaem.2024.0481"},"language":"en","primary_location":{"id":"doi:10.47392/irjaem.2024.0481","doi":"https://doi.org/10.47392/irjaem.2024.0481","is_oa":true,"landing_page_url":"https://doi.org/10.47392/irjaem.2024.0481","pdf_url":null,"source":{"id":"https://openalex.org/S5407010595","display_name":"International Research Journal on Advanced Engineering and Management (IRJAEM)","issn_l":"2584-2854","issn":["2584-2854"],"is_oa":true,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":null,"host_organization_name":null,"host_organization_lineage":[],"host_organization_lineage_names":[],"type":"journal"},"license":"cc-by-nc","license_id":"https://openalex.org/licenses/cc-by-nc","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"International Research Journal on Advanced Engineering and Management (IRJAEM)","raw_type":"journal-article"},"volume":null,"type":"article","is_traditional":true,"indexed_in":["crossref"],"open_access":{"is_oa":true,"oa_status":"diamond","oa_url":"https://doi.org/10.47392/irjaem.2024.0481","any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5104542762","display_name":"Prashant A. Patil","orcid":"https://orcid.org/0009-0001-2941-1941","observed_orcids":["https://orcid.org/0009-0001-2941-1941"]},"institutions":[{"id":"https://openalex.org/I4210145051","display_name":"Megafine Pharma (India)","ror":"https://ror.org/04n7kzx92","country_code":"IN","type":"company","lineage":["https://openalex.org/I4210145051"]}],"countries":["IN"],"is_corresponding":false,"raw_author_name":"Prashant A. Patil","raw_affiliation_strings":["Department of Process Research and Development, Megafine Pharma (P) Ltd., 201, Lakhmapur, Dindori, Nashik, Maharashtra, India"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Process Research and Development, Megafine Pharma (P) Ltd., 201, Lakhmapur, Dindori, Nashik, Maharashtra, India","institution_ids":["https://openalex.org/I4210145051"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5001552341","display_name":"Sneha N. Tambat","orcid":"https://orcid.org/0000-0002-3709-2418","observed_orcids":["https://orcid.org/0000-0002-3709-2418"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Sneha N. Tambat","raw_affiliation_strings":["Department of Chemistry School of Science Sandip University, Nashik, Maharashtra, India"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Chemistry School of Science Sandip University, Nashik, Maharashtra, India","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5006728682","display_name":"Dilip R. Birari","orcid":"https://orcid.org/0009-0006-0152-7164","observed_orcids":["https://orcid.org/0009-0006-0152-7164"]},"institutions":[{"id":"https://openalex.org/I4210145051","display_name":"Megafine Pharma (India)","ror":"https://ror.org/04n7kzx92","country_code":"IN","type":"company","lineage":["https://openalex.org/I4210145051"]}],"countries":["IN"],"is_corresponding":false,"raw_author_name":"Dilip R. Birari","raw_affiliation_strings":["Department of Process Research and Development, Megafine Pharma (P) Ltd., 201, Lakhmapur, Dindori, Nashik, Maharashtra, India"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Process Research and Development, Megafine Pharma (P) Ltd., 201, Lakhmapur, Dindori, Nashik, Maharashtra, India","institution_ids":["https://openalex.org/I4210145051"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5027552418","display_name":"Pritesh B. Kardile","orcid":"https://orcid.org/0009-0001-4142-5473","observed_orcids":["https://orcid.org/0009-0001-4142-5473"]},"institutions":[{"id":"https://openalex.org/I4210145051","display_name":"Megafine Pharma (India)","ror":"https://ror.org/04n7kzx92","country_code":"IN","type":"company","lineage":["https://openalex.org/I4210145051"]}],"countries":["IN"],"is_corresponding":false,"raw_author_name":"Pritesh Kardile","raw_affiliation_strings":["Department of Process Research and Development, Megafine Pharma (P) Ltd., 201, Lakhmapur, Dindori, Nashik, Maharashtra, India"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Process Research and Development, Megafine Pharma (P) Ltd., 201, Lakhmapur, Dindori, Nashik, Maharashtra, India","institution_ids":["https://openalex.org/I4210145051"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5114697733","display_name":"Mubarak Ali R. Sayyed","orcid":"https://orcid.org/0009-0002-3815-0111","observed_orcids":["https://orcid.org/0009-0002-3815-0111"]},"institutions":[{"id":"https://openalex.org/I4210145051","display_name":"Megafine Pharma (India)","ror":"https://ror.org/04n7kzx92","country_code":"IN","type":"company","lineage":["https://openalex.org/I4210145051"]}],"countries":["IN"],"is_corresponding":false,"raw_author_name":"Mubarak Ali Sayyed","raw_affiliation_strings":["Department of Process Research and Development, Megafine Pharma (P) Ltd., 201, Lakhmapur, Dindori, Nashik, Maharashtra, India"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Process Research and Development, Megafine Pharma (P) Ltd., 201, Lakhmapur, Dindori, Nashik, Maharashtra, India","institution_ids":["https://openalex.org/I4210145051"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":1,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":0.0,"has_fulltext":false,"cited_by_count":0,"citation_normalized_percentile":{"value":0.0,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":null,"biblio":{"volume":"2","issue":"11","first_page":"3265","last_page":"3272"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T11460","display_name":"Analytical Methods in Pharmaceuticals","score":0.8432999849319458,"subfield":{"id":"https://openalex.org/subfields/1602","display_name":"Analytical Chemistry"},"field":{"id":"https://openalex.org/fields/16","display_name":"Chemistry"},"domain":{"id":"https://openalex.org/domains/3","display_name":"Physical Sciences"}},"topics":[{"id":"https://openalex.org/T11460","display_name":"Analytical Methods in Pharmaceuticals","score":0.8432999849319458,"subfield":{"id":"https://openalex.org/subfields/1602","display_name":"Analytical Chemistry"},"field":{"id":"https://openalex.org/fields/16","display_name":"Chemistry"},"domain":{"id":"https://openalex.org/domains/3","display_name":"Physical Sciences"}},{"id":"https://openalex.org/T10908","display_name":"Analytical Chemistry and Chromatography","score":0.06509999930858612,"subfield":{"id":"https://openalex.org/subfields/1602","display_name":"Analytical Chemistry"},"field":{"id":"https://openalex.org/fields/16","display_name":"Chemistry"},"domain":{"id":"https://openalex.org/domains/3","display_name":"Physical Sciences"}},{"id":"https://openalex.org/T12527","display_name":"Chemistry and Stereochemistry Studies","score":0.03669999912381172,"subfield":{"id":"https://openalex.org/subfields/1605","display_name":"Organic Chemistry"},"field":{"id":"https://openalex.org/fields/16","display_name":"Chemistry"},"domain":{"id":"https://openalex.org/domains/3","display_name":"Physical Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/mirabegron","display_name":"mirabegron","score":0.9599999785423279},{"id":"https://openalex.org/keywords/chiral-impurities","display_name":"chiral impurities","score":0.9750000238418579},{"id":"https://openalex.org/keywords/overactive-bladder","display_name":"overactive bladder","score":0.7730000019073486},{"id":"https://openalex.org/keywords/impurity-identification","display_name":"impurity identification","score":0.45100000500679016},{"id":"https://openalex.org/keywords/quality-control","display_name":"quality control","score":0.7820000052452087},{"id":"https://openalex.org/keywords/ich-guidelines","display_name":"ICH guidelines","score":0.7540000081062317},{"id":"https://openalex.org/keywords/chiral-centers","display_name":"stereogenic centers","score":0.3580000102519989}],"concepts":[{"id":"https://openalex.org/C2778164427","wikidata":"https://www.wikidata.org/wiki/Q3702534","display_name":"Mirabegron","level":4,"score":0.9664863348007202},{"id":"https://openalex.org/C2778941218","wikidata":"https://www.wikidata.org/wiki/Q331231","display_name":"Overactive bladder","level":3,"score":0.8816969394683838},{"id":"https://openalex.org/C2780035454","wikidata":"https://www.wikidata.org/wiki/Q8386","display_name":"Drug","level":2,"score":0.5950360298156738},{"id":"https://openalex.org/C71987851","wikidata":"https://www.wikidata.org/wiki/Q7216430","display_name":"Impurity","level":2,"score":0.532524585723877},{"id":"https://openalex.org/C126894567","wikidata":"https://www.wikidata.org/wiki/Q105650","display_name":"Urology","level":1,"score":0.5249863862991333},{"id":"https://openalex.org/C2780841128","wikidata":"https://www.wikidata.org/wiki/Q5073781","display_name":"Characterization (materials science)","level":2,"score":0.43470102548599243},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.4302990734577179},{"id":"https://openalex.org/C98274493","wikidata":"https://www.wikidata.org/wiki/Q128406","display_name":"Pharmacology","level":1,"score":0.3923443555831909},{"id":"https://openalex.org/C185592680","wikidata":"https://www.wikidata.org/wiki/Q2329","display_name":"Chemistry","level":0,"score":0.3493172526359558},{"id":"https://openalex.org/C192562407","wikidata":"https://www.wikidata.org/wiki/Q228736","display_name":"Materials science","level":0,"score":0.348909854888916},{"id":"https://openalex.org/C171250308","wikidata":"https://www.wikidata.org/wiki/Q11468","display_name":"Nanotechnology","level":1,"score":0.2749253511428833},{"id":"https://openalex.org/C178790620","wikidata":"https://www.wikidata.org/wiki/Q11351","display_name":"Organic chemistry","level":1,"score":0.11124911904335022},{"id":"https://openalex.org/C142724271","wikidata":"https://www.wikidata.org/wiki/Q7208","display_name":"Pathology","level":1,"score":0.059269875288009644},{"id":"https://openalex.org/C204787440","wikidata":"https://www.wikidata.org/wiki/Q188504","display_name":"Alternative medicine","level":2,"score":0.05022776126861572}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.47392/irjaem.2024.0481","doi":"https://doi.org/10.47392/irjaem.2024.0481","is_oa":true,"landing_page_url":"https://doi.org/10.47392/irjaem.2024.0481","pdf_url":null,"source":{"id":"https://openalex.org/S5407010595","display_name":"International Research Journal on Advanced Engineering and Management (IRJAEM)","issn_l":"2584-2854","issn":["2584-2854"],"is_oa":true,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":null,"host_organization_name":null,"host_organization_lineage":[],"host_organization_lineage_names":[],"type":"journal"},"license":"cc-by-nc","license_id":"https://openalex.org/licenses/cc-by-nc","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"International Research Journal on Advanced Engineering and Management (IRJAEM)","raw_type":"journal-article"}],"best_oa_location":{"id":"doi:10.47392/irjaem.2024.0481","doi":"https://doi.org/10.47392/irjaem.2024.0481","is_oa":true,"landing_page_url":"https://doi.org/10.47392/irjaem.2024.0481","pdf_url":null,"source":{"id":"https://openalex.org/S5407010595","display_name":"International Research Journal on Advanced Engineering and Management (IRJAEM)","issn_l":"2584-2854","issn":["2584-2854"],"is_oa":true,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":null,"host_organization_name":null,"host_organization_lineage":[],"host_organization_lineage_names":[],"type":"journal"},"license":"cc-by-nc","license_id":"https://openalex.org/licenses/cc-by-nc","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"International Research Journal on Advanced Engineering and Management (IRJAEM)","raw_type":"journal-article"},"sustainable_development_goals":[{"display_name":"Good health and well-being","score":0.4000000059604645,"id":"https://metadata.un.org/sdg/3"}],"study_designs":[],"awards":[],"funders":[],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W4312928212","https://openalex.org/W2601583358","https://openalex.org/W4400649706","https://openalex.org/W4247339214","https://openalex.org/W2057563553","https://openalex.org/W2588001201","https://openalex.org/W2156045663","https://openalex.org/W2606690808","https://openalex.org/W2854987671","https://openalex.org/W3210582235"],"abstract_inverted_index":{"Mirabegron":[0,21,148],"is":[1,10,22,37,71,85],"used":[2],"to":[3,57,76,101,140],"treat":[4],"overactive":[5],"bladder":[6],"that":[7],"drug":[8,69,103,122,149],"substance":[9,70,123,150],"the":[11,60,65,81,95,108,147],"first":[12],"\u03b23-adrenoreceptor":[13],"(AR)":[14],"agonist.":[15],"The":[16],"mechanism":[17,98],"of":[18,20,63,68,110,113],"action":[19],"as":[23,151],"an":[24,53],"adrenergic":[25],"beta-3-Agonist":[26],"and":[27,32,40,45,73,92,120,124,131,142],"cytochrome":[28],"P450":[29],"3A":[30],"inhibitor,":[31],"p-Glycoprotein":[33],"inhibitor.":[34],"This":[35,133],"molecule":[36],"optical":[38],"active":[39],"having":[41],"one":[42],"chiral":[43,66,111],"center":[44],"only":[46],"(R)-Mirabegron":[47],"presents":[48],"pharmacological":[49],"activity":[50],"being":[51],"(S)-Mirabegron":[52],"impurity":[54,67,84],"which":[55],"critical":[56],"control.":[58],"During":[59],"process":[61],"development":[62],"Mirabegron,":[64],"challenging":[72,75],"also":[74],"all":[77],"pharmaceutical":[78],"industries":[79],"too,":[80],"opposite":[82],"isomeric":[83],"introduced":[86],"form":[87],"its":[88,121],"key":[89,117],"starting":[90,118],"material":[91,119],"it":[93],"follows":[94],"same":[96],"reaction":[97],"path":[99],"up":[100],"final":[102],"substance,":[104],"present":[105],"work":[106,134],"describe":[107],"synthesis":[109],"impurities":[112,145],"each":[114],"intermediate,":[115],"including":[116],"their":[125],"characterization":[126],"by":[127],"spectral":[128],"data":[129],"(MS,1H-NMR":[130],"13C-NMR).":[132],"will":[135],"help":[136],"quality":[137],"control":[138,143],"(QC)":[139],"identify":[141],"these":[144],"in":[146],"per":[152],"ICH":[153],"guideline.":[154]},"counts_by_year":[],"updated_date":"2026-10-12T09:40:04.860316","created_date":"2024-11-19T00:00:00"}